Literature DB >> 15075179

Poly(ADP-ribose) polymerase and renal hypothermic preservation injury.

Martin J Mangino1, Mary Ametani, Csaba Szabó, James H Southard.   

Abstract

The nuclear enzyme poly(ADP-ribose) polymerase (PARP) has been implicated in ischemia-reperfusion injury in many tissues under normothermic conditions. The purpose of this study was to determine whether PARP contributes to mechanisms of the hypothermic ischemia-reperfusion injury that occurs when kidneys are cold stored for transplantation. Cortical tissue slice PARP enzyme activity rose significantly with prolonged cold storage and was dependent on both reperfusion and preservation quality. However, prior exposure to warm ischemia abrogated this increase. PARP protein increased with cold storage but was not dependent on reperfusion. PARP enzyme activity rose quickly after reperfusion in buffer and was not different when whole blood was used. Addition of exogenous hydrogen peroxide (3 mM) to normal renal slices significantly increased PARP activity over 4 h in the cortex but not in the medulla, but the medullary basal PARP synthesis rate was five times higher than that in the cortex. However, the reactive oxygen species (ROS) inhibitors catalase (2,000 U/ml), Trolox (200 microM), and DMSO (15 mM) did not reduce reperfusion-induced PARP activity in cold-stored cortical slices. Finally, PARP inhibitors potentiated preservation injury in isolated canine proximal renal tubules. In conclusion, canine renal PARP enzyme activity rises with prolonged cold storage after reperfusion and may play a protective rather than an injurious role in hypothermic preservation for transplantation. ROS are sufficient but not necessary to activate PARP under these conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15075179     DOI: 10.1152/ajprenal.00230.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

Review 1.  Delayed graft function in the kidney transplant.

Authors:  A Siedlecki; W Irish; D C Brennan
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

Review 2.  The role of innate immunity in donor organ procurement.

Authors:  Dianne B McKay
Journal:  Semin Immunopathol       Date:  2011-03-23       Impact factor: 9.623

Review 3.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

4.  Protective effects of ezrin on cold storage preservation injury in the pig kidney proximal tubular epithelial cell line (LLC-PK1).

Authors:  Tao Tian; Susanne L Lindell; Scott C Henderson; Martin J Mangino
Journal:  Transplantation       Date:  2009-05-27       Impact factor: 4.939

5.  PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia.

Authors:  Raimundo M G del Moral; Mercedes Gómez-Morales; Pedro Hernández-Cortés; David Aguilar; Trinidad Caballero; Jose Aneiros-Fernández; Mercedes Caba-Molina; M Dolores Rodríguez-Martínez; Andreina Peralta; Pablo Galindo-Moreno; Antonio Osuna; F Javier Oliver; Raimundo G del Moral; Francisco O'Valle
Journal:  ScientificWorldJournal       Date:  2013-11-11

6.  Poly[ADP-ribose] polymerase-1 expression is related to cold ischemia, acute tubular necrosis, and delayed renal function in kidney transplantation.

Authors:  Francisco O'Valle; Raimundo G M Del Moral; María del Carmén Benítez; David Martín-Oliva; Mercedes Gómez-Morales; David Aguilar; José Aneiros-Fernández; Pedro Hernández-Cortés; Antonio Osuna; Francesc Moreso; Daniel Serón; Francisco J Oliver; Raimundo G Del Moral
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

7.  Mouse IPK: A Powerful Tool to Partially Characterize Renal Reperfusion and Preservation Injury.

Authors:  Susanne L Lindell; Natascha Williams; Ilia Brusilovsky; Martin J Mangino
Journal:  Open Transplant J       Date:  2011-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.